The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Full Waveform Inversion (FWI) is capable of finely characterizing the velocity structure, anisotropy, viscoelasticity, and attenuation properties of subsurface media, which provides critical ...